Rising R&D Investment and Government Support Fuel Expansion of Global Duchenne Muscular Dystrophy Drugs Market

24 Oct 2023
www.prnewswire.com
Orphan DrugGene Therapy
DUBLIN, Oct. 24, 2023 /PRNewswire/ -- The "Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report" report has been added to
ResearchAndMarkets.com's offering.
The global market for Duchenne Muscular Dystrophy Drugs, valued at US$2 billion in 2022, is projected to grow to US$27.4 billion by 2030, with a remarkable compound annual growth rate (CAGR) of 39.1% during the analysis period of 2022-2030.
Among the segments analyzed in the report, Exon Skipping is expected to lead the growth with a CAGR of 44.9%, reaching US$18.1 billion by the end of the forecast period. The Steroid Therapy segment is estimated to grow at a CAGR of 27.7% over the next 8 years.
Key Market Insights:
The U.S. Duchenne Muscular Dystrophy Drugs market is estimated at US$843.1 million in 2022.
China, the world's second-largest economy, is forecasted to reach a market size of US$2.4 billion by 2030, with a CAGR of 46%.
Japan and Canada are also noteworthy markets, expected to grow at 32.6% and 31.7% respectively from 2022 to 2030.
Within Europe, Germany is forecasted to grow at approximately 34.8% CAGR.
Select Competitors:
Key players in the Duchenne Muscular Dystrophy Drugs market include:
Economic Outlook:
The global economic outlook is showing signs of improvement, with growth recovery expected in the near term. While challenges such as slower-than-expected decline in global headline inflation, food and fuel inflation in developing countries, and high retail inflation persist, countries and governments are taking measures to address these issues.
The rise of new technologies, including generative AI, applied AI, machine learning, next-generation software development, Web3, cloud and edge computing, quantum technologies, electrification, renewables, and climate technologies, is expected to open up new opportunities in the global investment landscape. These technologies have the potential to drive incremental growth and value to global GDP.
The short-term economic landscape is expected to be a mix of challenges and opportunities, requiring resilience and adaptability from businesses and their leaders.
For more detailed insights into the Duchenne Muscular Dystrophy Drugs market and global economic trends, please refer to the full report.
What`s New?
Special discussions on the global economic climate and market sentiment
Coverage on global competitiveness and key competitor percentage market shares
Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and research platform
Complimentary updates for one year
Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Global Economic Update
From Pandemic to War & Inflation: "Gloomy Outlook for 2023 Despite Signs of Easing Inflationary Conditions
Here's How Inflationary Pressures Affect the Economy
Here's What's Causing Inflationary Pressures in the Global Market
Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue
Global Economy Faces a Tough Climb Towards Recovery Made Rockier by the War, Anti-Inflation Fiscal Policies & Slower Than Desirable Easing of Inflationary Pressures: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
Impact of COVID-19 on Duchenne Muscular Dystrophy Drugs Market
Competition
Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market
Duchenne Muscular Dystrophy Drugs - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
Global Market Overview and Prospects
Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence
A Review of the Approved DMD Drugs
North America and Europe to Remain Lucrative Markets
Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market
Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing
Market Drivers
Rising Incidence of DMD to Catalyze Growth
DMD Prevalence (in 100,000 Population) in Select Countries: 2020
High Uptake of Novel Therapies & Drugs
Market Restraints & Challenges
Lack of Standardization for Clinical Efficacy
Stringent Regulatory Regime
Market Opportunities
Product Developments & Rising Awareness
Surge in Clinical Trials to Launch Novel Options
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising R&D Investment to Boost DMD Market
Select Therapy Candidates Under Development for Treating DMD
Growing Government Support Propels Market Expansion
Biologics - The Most Dynamic Segment of the Market
Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain
Gene Therapy for DMD Treatment
Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD)
Children's National Hospital Starts Offering Newly Approved Gene Therapy for DMD
Promising Gene Therapies
Potential Side-Effects & Risks of Gene Therapies
Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods
DT-DEC01 Offers Promise to Stabilize or Improve Motor Function
AOC 1044 Receives Orphan Drug Status for DMD44
Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy
Uptrend in Healthcare Expenditure Creates Substantial Opportunities
World Healthcare Expenditure (In US$ Trillion) for the Years 2019, 2021 & 2023
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/7fholv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.